Plasma Galectin-4 and Charcot-Leyden Crystal Protein/Galectin-10 as Emerging Biomarkers of Metabolically Induced Inflammation in Patients with Psoriasis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110339 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Anna Baran und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland. Hauptthemen laut MEDLINE: Galectins, Psoriasis, Galectin 4, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Białystok.
Abstract (Originalsprache)
Psoriasis is a complex inflammatory disease related to cardiometabolic disorders (CMDs). Galectin-4 (gal-4) is involved in biological processes such as lipid raft stabilization, intestinal inflammation and tumorigenesis. Charcot-Leyden crystals (CLCs), inter alia, Charcot-Leyden crystal/galectin-10 (CLC/gal-10), are involved in eosinophil-derived diseases. To date, neither of these galectins has been investigated in the context of psoriasis. The study aimed to evaluate serum galectin-4 and -10 levels in psoriatic patients and explore potential relationships with disease activity, metabolic or inflammatory indices. Blood samples were collected from 60 patients with plaque-type psoriasis and 30 healthy volunteers and evaluated using an Enzyme-Linked Immunosorbent Assay (ELISA). Morphological and biochemical indices were measured using routine laboratory techniques. Plasma gal-4 and gal-10 concentrations were significantly higher in patients with psoriasis than in the control group (p < 0.05). Galectins did not correlate with the Psoriasis Area Severity Index (PASI) nor age (p > 0.5); however, gal-4 showed a significant positive correlation with Body Mass Index (BMI), psoriasis duration (p = 0.03), and transaminase activity. Both proteins were the highest in obese psoriatics (p < 0.05). The results indicate that galectin-4 and galectin-10 may be involved in the pathophysiological mechanisms underlying CMDs in psoriatics. These galectins represent promising candidates for biomarkers of metabolically driven inflammation, with galectin-4, in particular, emerging as a potential indicator of hepatic dysfunction in psoriatic patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland.
- Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C St., 15-089 Bialystok, Poland.
ORCID-Profile: Anna Baran, Julia Nowowiejska, Julia Parzych, Justyna Magdalena Hermanowicz, Dariusz Pawlak, Iwona Flisiak
Förderung
- Medical University of Białystok
Zitieren
APA
Baran, A., Nowowiejska, J., Parzych, J., Hermanowicz, J. M., Sieklucka, B., Pawlak, D., & Flisiak, I. (2025). Plasma Galectin-4 and Charcot-Leyden Crystal Protein/Galectin-10 as Emerging Biomarkers of Metabolically Induced Inflammation in Patients with Psoriasis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110339
Vancouver
Baran A, Nowowiejska J, Parzych J, Hermanowicz JM, Sieklucka B, Pawlak D, et al. Plasma Galectin-4 and Charcot-Leyden Crystal Protein/Galectin-10 as Emerging Biomarkers of Metabolically Induced Inflammation in Patients with Psoriasis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110339
BibTeX
@article{Baran2025,
author = {Baran, Anna and Nowowiejska, Julia and Parzych, Julia and Hermanowicz, Justyna Magdalena and Sieklucka, Beata and Pawlak, Dariusz and Flisiak, Iwona},
title = {Plasma Galectin-4 and Charcot-Leyden Crystal Protein/Galectin-10 as Emerging Biomarkers of Metabolically Induced Inflammation in Patients with Psoriasis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110339}
}
EUVIMED